Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Latham

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Transplantation Proceedings|May 1, 1997
Small bowel transplantation under oral immunosuppression: experimental study in the pigG Rossi, S Gatti, P Reggiani, et al.
Molecular Genetics and Metabolism|June 24, 2017
Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathyXin Xu, Amy Q Wang, Lea L Latham, et al.
Elife|June 10, 2020
Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinomaJordan F Hastings, Alvaro Gonzalez Rajal, Sharissa L Latham, et al.
Nursing Outlook|September 13, 2024
Call to action: Blueprint for change in acute and critical care nursingMartha A Q Curley, Margarete L Zalon, Maureen A Seckel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 10, 2024
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical SettingsCelia Jonsson-Oldenbüttel, Jade Ghosn, Marc van der Valk, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Nature Communications|February 21, 2025
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Breast Cancer Research : BCR|March 23, 2019
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSean P Kennedy, Jeremy Z R Han, Neil Portman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureChloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Transplantation Proceedings|May 1, 1997
Small bowel transplantation under oral immunosuppression: experimental study in the pigG Rossi, S Gatti, P Reggiani, et al.
Molecular Genetics and Metabolism|June 24, 2017
Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathyXin Xu, Amy Q Wang, Lea L Latham, et al.
Elife|June 10, 2020
Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinomaJordan F Hastings, Alvaro Gonzalez Rajal, Sharissa L Latham, et al.
Nursing Outlook|September 13, 2024
Call to action: Blueprint for change in acute and critical care nursingMartha A Q Curley, Margarete L Zalon, Maureen A Seckel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 10, 2024
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical SettingsCelia Jonsson-Oldenbüttel, Jade Ghosn, Marc van der Valk, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Nature Communications|February 21, 2025
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Breast Cancer Research : BCR|March 23, 2019
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSean P Kennedy, Jeremy Z R Han, Neil Portman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureChloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
Pageof 10